###begin article-title 0
Eukaryotic Initiation Factor 2B (eIF2B) GEF Activity as a Diagnostic Tool for EIF2B-Related Disorders
###end article-title 0
###begin p 1
Conceived and designed the experiments: OBT AF. Performed the experiments: LH AH MCC AF. Analyzed the data: LO RS PB OBT AF. Contributed reagents/materials/analysis tools: CG. Wrote the paper: RS OBT AF.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 656 664 <span type="species:ncbi:9606">patients</span>
###xml 1170 1178 <span type="species:ncbi:9606">patients</span>
In recent years, the phenotypes of leukodystrophies linked to mutations in the eukaryotic initiation factor 2B genes have been extended, classically called CACH/VWM (Childhood ataxia with cntral hypomyelination/vanishing white matter disorder). The large clinical spectrum observed from the more severe antenatal forms responsible for fetal death to milder adult forms with an onset after 16 years old and restricted to slow cognitive impairment have lead to the concept of eIF2B-related disorders. The typical MRI pattern with a diffuse CSF-like aspect of the cerebral white matter can lack particularly in the adult forms whereas an increasing number of patients with clinical and MRI criteria for CACH/VWM disease but without eIF2B mutations are found. Then we propose the use of biochemical markers to help in this difficult diagnosis. The biochemical diagnosis of eIF2B-related disorder is difficult as no marker, except the recently described asialotransferrin/transferrin ratio measured in cerebrospinal fluid, has been proposed and validated until now. Decreased eIF2B GEF activity has been previously reported in lymphoblastoid cell lines from 30 eIF2B-mutated patients. Our objective was to evaluate further the utility of this marker and to validate eIF2B GEF activity in a larger cohort as a specific diagnostic test for eIF2B-related disorders.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
We performed eIF2B GEF activity assays in cells from 63 patients presenting with different clinical forms and eIF2B mutations in comparison to controls but also to patients with defined leukodystrophies or CACH/VWM-like diseases without eIF2B mutations. We found a significant decrease of GEF activity in cells from eIF2B-mutated patients with 100% specificity and 89% sensitivity when the activity threshold was set at </=77.5%.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 64 72 <span type="species:ncbi:9606">patients</span>
These results validate the measurement of eIF2B GEF activity in patients' transformed-lymphocytes as an important tool for the diagnosis of eIF2B-related disorders.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1</italic>
###xml 24 25 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</italic>
###xml 276 279 276 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Schiffmann1">[1]</xref>
###xml 281 284 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-vanderKnaap1">[2]</xref>
###xml 286 289 286 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Leegwater1">[3]</xref>
###xml 291 294 291 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-vanderKnaap2">[4]</xref>
###xml 403 406 403 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli1">[5]</xref>
###xml 408 411 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Labauge1">[6]</xref>
###xml 683 686 683 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Schiffmann1">[1]</xref>
###xml 688 691 688 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Leegwater1">[3]</xref>
###xml 778 781 778 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli2">[7]</xref>
###xml 848 851 848 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-vanderKnaap3">[8]</xref>
###xml 950 953 950 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Labauge1">[6]</xref>
###xml 955 958 955 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli3">[9]</xref>
Mutations in the EIF2B1-5 genes (OMIM 606686, 606454, 606273, 606687, 603945) encoding the subunits of the ubiquitously expressed eukaryotic initiation factor 2B (eIF2B) have been reported in a group of clinically heterogeneous leukodystrophies termed eIF2B-related disorders [1], [2], [3], [4]. Disease severity is correlated with age at disease onset, with stress onset trigger or aggravating factors [5], [6]. A large clinical spectrum is observed and several distinct forms have been proposed: i) the classical childhood ataxia with central hypomyelination/vanishing white matter disease (CACH/VWM, OMIM 603896), with progressive neurological deterioration between age 2-5 years [1], [3], ii) the infantile severe forms with disease onset <2 years and rapid fatal evolution [7], iii) the most severe antenatal forms responsible for fetal death [8], and iv) the milder forms with disease onset >5 years and restricted to slow cognitive impairment [6], [9].
###end p 9
###begin p 10
###xml 193 201 193 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Schiffmann2">[10]</xref>
###xml 379 387 379 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 564 572 564 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 542 550 <span type="species:ncbi:9606">patients</span>
The typical MRI pattern shows a diffuse CSF-like aspect of the cerebral white matter of the cerebral hemispheres and this pattern recognition permits the selection of patients eligible for the EIF2B1-5 genes sequencing [10]. But MRI can lack particularly in the adult forms whereas an increasing number of patients with clinical and MRI criteria for CACH/VWM disease but without EIF2B1-5 genes mutations (CACH/VWM-like) are found, underlining the necessity to have biochemical markers to help in the diagnosis process and in the selection of patients eligible for EIF2B1-5 direct sequencing.
###end p 10
###begin p 11
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Vanderver1">[11]</xref>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Vanderver2">[12]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
###xml 577 581 577 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Gomez1">[14]</xref>
###xml 620 628 <span type="species:ncbi:9606">patients</span>
###xml 787 795 <span type="species:ncbi:9606">patients</span>
###xml 909 917 <span type="species:ncbi:9606">patients</span>
###xml 1027 1035 <span type="species:ncbi:9606">patients</span>
###xml 1114 1122 <span type="species:ncbi:9606">patients</span>
Two biochemical markers have been recently proposed as potential tools for the screening of eIF2B-related disorders: the decrease of asialotransferrin/total transferrin in CSF [11], [12], and the decrease of the eIF2B GEF activity measured in Epstein-Barr Virus (EBV)-transformed lymphocytes or lymphoblasts (LLB) [13]. In fact, eIF2B is a key regulator of the protein synthesis particularly under cellular stresses through its nucleotide guanine exchange (GEF) activity: it converts the initiation factor 2 (eIF2) from an inactive GDP-bound form to an active eIF2-GTP complex [14]. Measurement of eIF2B GEF activity in patients' LLB has been proposed as a potential diagnostic tool relating to a previous work showing decrease of this GEF activity in LLB from 30 affected eIF2B-mutated patients in comparison to controls. In order to further evaluate the specificity and sensitivity of eIF2B GEF activity in patients' LLB regarding the diagnosis of eIF2B-related disorders, we extended this initial cohort of 30 to 63 mutated patients and compared the results not only to healthy non mutated subjects but also to patients with defined leukodystrophies or CACH/VWM-like diseases.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Objectives
###end title 13
###begin p 14
###xml 155 163 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 505 513 <span type="species:ncbi:9606">patients</span>
Our hypothesis is that eIF2B GEF activity measurement in LLB is a specific and sensitive marker that would be powerful to select patients eligible for the EIF2B1-5 genes sequencing and then to help in the molecular diagnosis of eIF2B-related disorders. Our objective is then to extend our initial cohort of 30 [13] to 63 eIF2B-mutated patients and to compare the results to healthy subjects but also to CACH/VWM-like patients, in order to evaluate the specificity and sensitivity of eIF2B GEF activity in patients' LLB regarding the diagnosis of eIF2B-related disorders.
###end p 14
###begin title 15
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 15
###begin p 16
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
###xml 153 160 153 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1</xref>
###xml 306 313 306 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t002">Table 2</xref>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
The GEF activity was measured in LLB from 63 eIF2B-mutated patients (including 30 patients already reported [13] and 13 patients never reported todate, (Table 1), 18 clinically healthy subjects (controls) and 38 patients with leukodystrophies of other causes, termed eIF2B-unrelated leukodystrophic group (Table 2). This last group included:
###end p 16
###begin p 17
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GFAP-</italic>
###xml 174 178 174 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLC1</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLP1</italic>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
19 leukodystrophic patients with an identified genetic defect and termed OL (other leukodystrophy)-patients: 9 GFAP-mutated patients (with Alexander disease, OMIM 203450), 5 MLC1-mutated patients (with megalencephalic leukoencephalopathy with cysts, OMIM 604004) and 5 PLP1-mutated patients (with Pelizaeus-Merzbacher disease, PMD, OMIM 312080);
###end p 17
###begin p 18
###xml 168 176 168 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
19 patients with the presence of clinical and/or MRI features observed in eIF2B-related disorders but screened negative for mutations in the coding regions of the five EIF2B1-5 genes genes, and termed CACH-VWM-like patients.
###end p 18
###begin title 19
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Clinical data and eIF2B GEF activity measured in lymphoblasts from the 63 eIF2B-mutated patients.
###end title 19
###begin p 20
###xml 149 152 149 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli1">[5]</xref>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
###xml 34 42 <span type="species:ncbi:9606">children</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
*  =  Familial form: two affected children in the same family; underlined: new patients whose genotype has not been reported in our previous studies [5], [13].
###end p 20
###begin p 21
###xml 44 47 44 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli1">[5]</xref>
score of disability as previously described [5]: 0: no neurologic signs, 1: stiff gait, 2: walk with help, 3: wheelchair-bound, 4: help for daily living, 5: death.
###end p 21
###begin p 22
Amino-acid numbers refer to the eIF2B peptide corresponding sequence.?  =  mutation not yet identified.
###end p 22
###begin p 23
###xml 150 154 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
Expressed as % control value +/- standard deviation (assays performed in triplicate); underlined: new eIF2B GEF activity measured and not reported in [13].
###end p 23
###begin p 24
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Vanderver1">[11]</xref>
###xml 58 62 58 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Vanderver2">[12]</xref>
Asialotransferrin ratio (AT) in % already described [11], [12]. NA: Not available.
###end p 24
###begin title 25
###xml 72 80 <span type="species:ncbi:9606">patients</span>
eIF2B GEF activity measured in lymphoblasts from the 38 leukodystrophic patients (19 OL and 19 CACH/VWM-like) and the 18 controls.
###end title 25
###begin p 26
OL: PMD: Pelizaeus-Merzbacher disease, AD: Alexander disease, MLC: Megalencephalic Leukoencephalopathy with Cysts; and CACH/VWM-like: CACH-L.
###end p 26
###begin p 27
?: second mutation not yet identified; NA: not available.
###end p 27
###begin p 28
###xml 150 154 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
Expressed as % control value +/- standard deviation (assays performed in triplicate); underlined: new eIF2B GEF activity measured and not reported in [13].
###end p 28
###begin title 29
Measurement of eIF2B GEF Activity in Transformed Lymphocytes
###end title 29
###begin p 30
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Neitzel1">[15]</xref>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
The direct GEF activity of the eIF2B complex was measured in triplicate in protein extracts from patients'EBV-transformed lymphocytes (LLB) as already described [13], [15].
###end p 30
###begin title 31
Ethics
###end title 31
###begin p 32
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
An Institutional Review Board of the participating centers (Comite de Protection des Personnes Sud-Est VI, 2009-A00188-49) approved the use of human subjects for this study. A written informed consent was obtained from all patients.
###end p 32
###begin title 33
Statistical Methods
###end title 33
###begin p 34
###xml 696 699 694 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli1">[5]</xref>
###xml 798 804 796 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 1096 1104 <span type="species:ncbi:9606">patients</span>
The eIF2B GEF activity was considered as a continuous variable and results are displayed as mean +/- SEM (standard error of the mean). Since the normality of eIF2B GEF (assessed by a Kolmogorov-Smirnov test) was not rejected, a one-way analysis of variance (ANOVA 1) was performed to assess the links between GEF activity and the patients'groups. On condition of a significant F-test for the ANOVA 1, a post-hoc multiple comparisons procedure was performed controlling for a 5% family-wise type I error using the Tukey honestly significant difference (THSD) test. A Spearman correlation coefficient (r) was calculated between GEF activity and age at disease onset (correleted to disease severity [5]). The Receiver Operating Characteristic, or ROC curve analysis (graphical plot of the sensitivity versus (1-specificity) for a binary classifier system as its discrimination threshold is varied), was performed on MedCalc(R) (v10.4, Mariakerke, Belgium) to determine the optimal threshold of GEF activity which best discriminates between eIF2B-mutated (n = 63) and eIF2B-unrelated leukodystrophic patients (n = 38), aiming a 100% specificity and the best associated sensitivity. The area under the ROC curve (AUC) was also estimated (with its 95% confidence limits) and tested towards 0.5. All remaining statistical analyses were performed on SAS(R) (v9.1, Cary, USA) with a type I error set at 5%.
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
###xml 39 47 <span type="species:ncbi:9606">Patients</span>
eIF2B GEF Activity in 63 eIF2B-Mutated Patients in Comparison to the Other Groups
###end title 36
###begin p 37
###xml 138 145 138 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1</xref>
###xml 244 253 242 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008318-g001">Figure 1A</xref>
###xml 597 605 589 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Tables 1</xref>
###xml 610 611 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t002">2</xref>
###xml 613 623 605 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008318-g001">Figures 1A</xref>
###xml 628 629 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008318-g002">2</xref>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
###xml 411 419 <span type="species:ncbi:9606">patients</span>
The eIF2B GEF activity was measured in LLB of 63 affected patients exhibiting various eIF2B mutations, age of onset and disease severity (Table 1). Despite the wide range of GEF activity in eIF2B-mutated cells (63.2+/-17.1%, range: 30-111.6%) (Figure 1A), multiple comparisons demonstrated a significant difference between the group of eIF2B-mutated patients (n = 63) and the three other groups of patients [OL-patients (104.1+/-11.4%, range: 80-133.6%, n = 19), CACH/VWM-like (99.6+/-10.3%, range: 82-119%, n = 19) and controls (98+/-3.3%, range: 88.5-102%, n = 18)] (F(3,115)  = 71.1, p<0.001) (Tables 1 and 2, Figures 1A and 2). The OL, CACH/VWM-like and controls groups had similar GEF activity (THSD test). The THSD test further detailed that only the eIF2B-mutated group had significantly lower GEF activity compared with each of the three other groups (OL, CACH/VWM-like and controls).
###end p 37
###begin title 38
###xml 16 24 <span type="species:ncbi:9606">patients</span>
Distribution of patients per classes of eIF2B GEF activity.
###end title 38
###begin p 39
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 185 186 185 186 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 406 409 406 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli1">[5]</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
A. Distribution of the patients'groups per classes of eIF2B GEF activity in %. The patients' groups are healthy controls, eIF2B-mutated, others leukodystrophies (OL) and CACH-VMW-like. B. Distribution of the 63 eIF2B-mutated patients per classes of eIF2B GEF activity. The mutated patients have been classified into three clinical groups depending of their clinical severity, according to previous studies [5]. Form 1: disease onse before 2 years, form 2: disease onset berween 2 and 5 years, form 3: disease onset >5 years.
###end p 39
###begin title 40
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Decreased eIF2B GEF activity in eIF2B-mutated patients' lymphoblasts (LLB).
###end title 40
###begin p 41
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
The eIF2B GEF activity was measured in LLB from 63 eIF2B-mutated patients in comparison to 8 healthy controls, 19 patients carrying other leukodystrophies (OL: 9 patients with Alexander disease, AD, 5 patients with Pelizaeus-Merzbacher disease, PMD, and 5 patients with Megalencephalic leukoencephalopathy with cysts, MLC), and 19 CACH/VWM-like patients without eIF2B mutations. Experiments were carried out in triplicate. Data are presented as percentage of exchange activity of control LLB. The statistical multiple comparisons analysis between all the seven groups showed significant differences (*) only for the eIF2B-mutated group (p<0.001).
###end p 41
###begin p 42
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 501 509 <span type="species:ncbi:9606">patients</span>
Pooling CACH/VWM-like patients and OL-patients (group of eIF2B-unrelated leukodystrophic patients, n = 38), the aforementioned comparison of GEF activity led still to a significant result (F(2,116)  = 106.1, p<0.0001) and the THSD test showed again the same significantly lower GEF activity in the eIF2B-mutated group as compared with each of the two other groups (eIF2B-unrelated leukodystrophic and controls). Then difference in GEF activity remained statistically significant between eIF2B-mutated patients and the other groups tested.
###end p 42
###begin title 43
Correlation between Age at Disease Onset and GEF Activity
###end title 43
###begin p 44
###xml 165 172 165 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1</xref>
###xml 589 596 583 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1</xref>
###xml 762 770 752 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1B</xref>
###xml 1081 1089 1071 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1B</xref>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 394 401 <span type="species:ncbi:9606">patient</span>
###xml 423 430 <span type="species:ncbi:9606">patient</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 834 842 <span type="species:ncbi:9606">patients</span>
###xml 883 891 <span type="species:ncbi:9606">patients</span>
###xml 999 1007 <span type="species:ncbi:9606">patients</span>
A weak correlation was found between GEF activity measured in the eIF2B-mutated LLB and age at disease onset (r = 0.4309, p = 0.0004). Two patients 356-1 and 432-1 (Table 1) exhibited high GEF activities (respectively 80.4+/-2.8% and 90.4+/-1.8%) despite a classical clinical form (disease onset at 3 years followed by severe disability within 3 years and death occurring after 16 years in one patient). On the other hand, patient 1388-1 affected with an adult onset, slowly progressive form (only stiff gait after 17 years of disease progression), exhibited a low GEF activity (39+/-7%) (Table 1). However, the eight patients with onset </=2 years (disease severity form 1) always had eIF2B GEF activity <55% (45.1+/-7.8%, mean age at disease onset: 1.2 year) (Table 1B). The correlation coefficient is higher in this group of eight patients (r = 0.68, p = 0.06) compared to the 30 patients carrying the clinical severity form 2 with onset between 2 and 5 years (r = 0.11, p = 0.52), and to the 25 patients carrying the severity form 3 with onset >5 years (r = 0.45, p = 0.0218) (Table 1B).
###end p 44
###begin title 45
ROC Curve Analysis of eIF2B GEF Activity in the Leukodystrophic Groups
###end title 45
###begin p 46
###xml 161 168 159 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1</xref>
###xml 566 574 560 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008318-g003">Figure 3</xref>
###xml 809 817 803 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 825 832 819 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1</xref>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 1012 1020 <span type="species:ncbi:9606">patients</span>
Three out of the 63 eIF2B-mutated patients (4.8%) had GEF activity >100%. They expressed a mild juvenile/adult form of the disease with onset >/=5 years of age (Table 1). The ROC curve analysis of eIF2B GEF activity performed towards differential diagnosis between eIF2B-related (n = 63) and eIF2B-unrelated (n = 38) leukodystrophy patients lead to a pathognomonic threshold "</=77.5% of GEF activity", achieving 100% specificity (95% CL = 90.7-100%) and 88.9% sensitivity (95% CL = 78.4-95.4%), with an almost perfect discrimination (AUC = 0.96+/-0.024, p<0.0001) (Figure 3). Only 7/63 (11.1%) eIF2B-mutated patients had GEF activities >77.5%. These patients presented with classic to milder clinical forms with onset ranging from 3 to 57 years, slow disease progression, and carrying mutations in different EIF2B1-5 genes (Table 1). This group illustrates that the high level of GEF activity found is not linked to the type of mutated gene nor to a specific degree of clinical severity. However, none of these patients had a disease onset <3 years.
###end p 46
###begin title 47
ROC (Receiver Operating Characteristic) curve of eIF2B GEF activity regarding the diagnosis of eIF2B-related disorders.
###end title 47
###begin p 48
###xml 180 188 <span type="species:ncbi:9606">patients</span>
The ROC curve analysis was performed to determine the optimal threshold of GEF activity which best discriminates between eIF2B-mutated (n = 63) and eIF2B-unrelated leukodystrophic patients (n = 38). The </=77.5% threshold achieves 100% specificity (95% CL = 90.7-100%) and 88.9% sensitivity (95% CL = 78.4-95.4%). The area under the ROC curve (AUC)  = 0.955; standard error  = 0.0244; 95% confidence interval: 0.894 to 0.986; test for the: AUC  = 0.5, p = 0.0001.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 467 475 465 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 714 722 712 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EIF2B1-5</italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 213 216 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 503 511 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
Analysis of this extended cohort showed that eIF2B GEF activity measured in patients' LLB distinguishes eIF2B-mutated patients from those with eIF2B-unrelated leukodystrophies with 100% positive predictive value (PPV) and 89% negative predictive value at </=77.5% threshold. At this threshold, the assay systematically excludes patients without eIF2B mutations. Therefore, it represents an interesting screening tool to select patients for a direct sequencing of the EIF2B1-5 genes. For leukodystrophic patients with >77.5% GEF activity, the probability to find eIF2B mutations is 15% (7/45) and increases to 26.9% (7/26) if patients have clinical and/or MRI features typical to eIF2B-related disorder. Therefore, EIF2B1-5 sequencing is still indicated for patients who are clinically suspected of eIF2B-related disorder with GEF activity >77.5%, particularly in milder forms.
###end p 50
###begin p 51
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Fogli4">[13]</xref>
###xml 281 290 281 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008318-g001">Figure 1B</xref>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
The wider range of disease onset reported in this cohort in comparison to previous work [13] may explain the weaker correlation found between age at disease onset and GEF activity. Such correlation is better in severe forms with GEF activity <55% for patients with onset <2 years (Figure 1B). Discrepancies in the GEF activity values were found among patients of the same group of disease onset or with the same mutations such as siblings 432-1 and 432-2 (GEF activities at respectively 90% and 53.9%), confirming that GEF activity in LLB is modulated by factors other than eIF2B mutations.
###end p 51
###begin p 52
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008318-Vanderver2">[12]</xref>
###xml 360 367 360 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008318-t001">Table 1</xref>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 392 399 <span type="species:ncbi:9606">patient</span>
###xml 558 565 <span type="species:ncbi:9606">patient</span>
###xml 646 649 <span type="species:ncbi:10796?0.09130166563849476|species:ncbi:12211?0.07279457125231338">PPV</span>
Determination of the asialotransferrin/total transferrin ratio in CSF is also a reliable marker to distinct eIF2B-mutated from non-mutated patients with 100% sensitivity and 94% specificity associated to 8%-ratio threshold [12]. This marker has been determined in parallel for five of our 63 eIF2B-mutated patients and a decreased ratio has been found in CSF (Table 1) in all five, including patient 432-1 with a surprisingly normal eIF2B GEF activity (90.4+/-1.8%) compared to his sibling. This suggests that these two biomarkers, if available for the same patient, may be complementary in order to assess with 100% sensitivity, specificity and PPV.
###end p 52
###begin title 53
Limitations
###end title 53
###begin p 54
Limitations of this study are:
###end p 54
###begin p 55
###xml 31 39 <span type="species:ncbi:9606">patients</span>
the relatively small number of patients overall, as eIF2B-related disorders are rare disorders;
###end p 55
###begin p 56
###xml 57 65 <span type="species:ncbi:9606">patients</span>
the age of disease onset, that may be imprecise for some patients, since it is determined retrospectively.
###end p 56
###begin p 57
###xml 51 59 <span type="species:ncbi:9606">patients</span>
We gratefully acknowledge the participation of the patients' families. We acknowledge Scot Kimball to provide us the eIF2 substrate.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
Childhood ataxia with diffuse central nervous system hypomyelination.
###end article-title 59
###begin article-title 60
A new leukoencephalopathy with vanishing white matter.
###end article-title 60
###begin article-title 61
Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter.
###end article-title 61
###begin article-title 62
Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter.
###end article-title 62
###begin article-title 63
The effect of genotype on the natural history of eIF2B-related leukodystrophies.
###end article-title 63
###begin article-title 64
Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases.
###end article-title 64
###begin article-title 65
Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus.
###end article-title 65
###begin article-title 66
eIF2B-related disorders: antenatal onset and involvement of multiple organs.
###end article-title 66
###begin article-title 67
Ovarian failure related to eukaryotic initiation factor 2B mutations.
###end article-title 67
###begin article-title 68
Invited article: an MRI-based approach to the diagnosis of white matter disorders.
###end article-title 68
###begin article-title 69
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Decreased asialotransferrin in cerebrospinal fluid of patients with Childhood-onset ataxia and central nervous system hypomyelination/Vanishing white matter disease.
###end article-title 69
###begin article-title 70
Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder.
###end article-title 70
###begin article-title 71
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients.
###end article-title 71
###begin article-title 72
Identification of domains and residues within the epsilon subunit of eukaryotic translation initiation factor 2B (eIF2Bepsilon) required for guanine nucleotide exchange reveals a novel activation function promoted by eIF2B complex formation.
###end article-title 72
###begin article-title 73
A routine method for the establishment of permanent growing lymphoblastoid cell lines.
###end article-title 73
###begin p 74
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 74
###begin p 75
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the ELA Foundation (2006-08). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 75

